This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Sanofi Nanofitins Program
Drug Names(s): Sanofi Nanofitins Program
Affilogic and Sanofi are developing a Nanofitin-conjugated biotherapeutic with a proprietary mechanism of action.
Nanofitins are small affinity proteins that can be conjugated to other moieties (small molecule, biologics, nanoparticles) by genetic fusion or standard chemistry (regio-selective conjugation).
Affilogic and Sanofi
In June 2016, Affilogic announced that it has applied its alternative scaffold technology, the Nanofitins, for a joint discovery and development of Nanofitins against an undisclosed target nominated by Sanofi. Affilogic selected Nanofitin candidates from their proprietary libraries for subsequent conjugation to Sanofi proprietary molecules.
Under the Research Collaboration and licensing agreement, Affilogic and Sanofi will combine research efforts to establish optimized Nanofitin-conjugated biotherapeutics and carry out further preclinical development of conjugates. Sanofi has obtained exclusivity on 2 different Nanofitin families and will have sole responsibility for all clinical development and commercial activities of such Nanofitin-conjugated biotherapeutics.
Under the terms of the agreement, Affilogic will grant worldwide exclusive rights to all the development projects and is entitled to receive research funding, future milestones...See full deal structure in Biomedtracker
Additional information available to subscribers only: